Format

Send to

Choose Destination
Nat Rev Cancer. 2019 Sep;19(9):481-482. doi: 10.1038/s41568-019-0172-2.

Preclinical rare cancer research to inform clinical trial design.

Barker HE1,2, Scott CL3,4,5,6,7.

Author information

1
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
2
Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia.
3
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. scottc@wehi.edu.au.
4
Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia. scottc@wehi.edu.au.
5
Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia. scottc@wehi.edu.au.
6
Royal Women's Hospital, Parkville, Victoria, Australia. scottc@wehi.edu.au.
7
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia. scottc@wehi.edu.au.
PMID:
31263218
DOI:
10.1038/s41568-019-0172-2

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center